Stay updated with breaking news from Q32 Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Piper Sandler started coverage on shares of Q32 Bio (NASDAQ:QTTB – Free Report) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $45.00 price target on the stock. Q32 Bio Stock Down 2.7 % QTTB stock opened at $20.71 on Tuesday. The company has a market cap of […]
/PRNewswire/ -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the...
Homology Medicines, Inc. (FIXX) on Thursday announced that it has entered into a definitive merger agreement with Q32 Bio Inc., a biotechnology company in an all-stock transaction.
/PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the...
/PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its...